E- Corbevax 2nd Made-In-India vaccine
- The government has booked 30 crore doses of Hyderabad-based Biological-E's Covid vaccine, which is still in clinical trials.
- The Health Ministry will make an advance payment of ₹ 1,500 crore to the company for what will be the second made-in-India vaccine to be used in the country after Bharat Biotech's Covaxin.
CORBEVAX
- Corbevax is a “recombinant protein sub-unit” vaccine, which means it is made up of a specific part of SARS-CoV-2 — the spike protein on the virus’s surface.
- The spike protein allows the virus to enter the cells in the body so that it can replicate and cause disease.
- However, when this protein alone is given to the body, it is not expected to be harmful as the rest of the virus is absent.
- The body is expected to develop an immune response against the injected spike protein.
- Therefore, when the real virus attempts to infect the body, it will already have an immune response ready that will make it unlikely for the person to fall severely ill.
- Although this technology has been used for decades to make hepatitis B vaccines, Corbevax will be among the first Covid-19 vaccines to use this platform.
- Like most other Covid-19 vaccines, Corbevax is administered in two doses.
HOW CORBEVAX IS DIFFERENT?
- Other Covid-19 vaccines approved so far are either mRNA vaccines (Pfizer and Moderna), Viral vector vaccines (AstraZeneca-Oxford/Covishield, Johnson & Johnson and Sputnik V) or Inactivated vaccines (Covaxin, Sinovac-CoronaVac and Sinopharm’s SARS-CoV-2 Vaccine–Vero Cell).
- On the other hand, Corbevax, like the mRNA and viral vector Covid-19 vaccines, targets only the spike protein, but in a different way.
- Viral vector and mRNA and vaccines use a code to induce our cells to make the spike proteins against which the body have to build immunity.
- In the case of Corbevax, the protein is actually being used.
BIOLOGICAL E
- Biological E, headquartered in Hyderabad, was founded by Dr D V K Raju in 1953 as a biological products company.
- It pioneered the production of heparin in India.
- By 1962, it forayed into the vaccines space, producing DPT vaccines on a large-scale.
Comments
Post a Comment